NTLA — Intellia Therapeutics Balance Sheet
0.000.00%
- $1.03bn
- $517.53m
- $57.88m
- 32
- 21
- 50
- 25
Annual balance sheet for Intellia Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 597 | 749 | 1,193 | 912 | 602 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.13 | 2.03 | 3.77 | 36.5 | 8.52 |
| Prepaid Expenses | |||||
| Total Current Assets | 617 | 769 | 1,217 | 998 | 640 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 55.1 | 100 | 161 | 148 | 247 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 676 | 1,294 | 1,520 | 1,301 | 1,191 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 64.3 | 126 | 127 | 115 | 111 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 149 | 254 | 285 | 251 | 319 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 527 | 1,040 | 1,236 | 1,050 | 872 |
| Total Liabilities & Shareholders' Equity | 676 | 1,294 | 1,520 | 1,301 | 1,191 |
| Total Common Shares Outstanding |